Rhumbline Advisers Silence Therapeutics PLC Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Rhumbline Advisers holds 6,196 shares of SLN stock, worth $34,635. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,196
Previous 1,875
230.45%
Holding current value
$34,635
Previous $5,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SLN
# of Institutions
55Shares Held
21.3MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$17 Million3.59% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$16.3 Million0.87% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$12.1 Million1.53% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.85MShares$10.3 Million0.9% of portfolio
-
Morgan Stanley New York, NY1.21MShares$6.77 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $201M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...